Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
3.555
-0.125 (-3.40%)
At close: Apr 28, 2026, 4:00 PM EDT
3.560
+0.005 (0.14%)
After-hours: Apr 28, 2026, 4:10 PM EDT
MRVI Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for MRVI stock have an average target of 4.13, with a low estimate of 2.00 and a high estimate of 5.00. The average target predicts an increase of 16.17% from the current stock price of 3.56.
Analyst Consensus: Buy
* Price targets were last updated on Dec 15, 2025.
Analyst Ratings
The average analyst rating for MRVI stock from 4 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 5 | 3 | 3 | 3 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 7 | 7 | 7 | 7 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Maintains $4 → $4.5 | Buy | Maintains | $4 → $4.5 | +26.58% | Dec 15, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $10 → $5 | Strong Buy | Maintains | $10 → $5 | +40.65% | Aug 12, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $7 → $5 | Buy | Maintains | $7 → $5 | +40.65% | Aug 12, 2025 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $12 → $10 | Strong Buy | Maintains | $12 → $10 | +181.29% | May 13, 2025 |
| Baird | Baird | Hold Maintains $3 → $2 | Hold | Maintains | $3 → $2 | -43.74% | May 13, 2025 |
Financial Forecast
Revenue This Year
209.03M
from 185.74M
Increased by 12.54%
Revenue Next Year
225.48M
from 209.03M
Increased by 7.87%
EPS This Year
-0.18
from -0.91
EPS Next Year
-0.15
from -0.18
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 218.7M | 239.4M | ||||||
| Avg | 209.0M | 225.5M | ||||||
| Low | 197.3M | 212.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 17.8% | 14.5% | ||||||
| Avg | 12.5% | 7.9% | ||||||
| Low | 6.2% | 1.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.13 | -0.09 | |||
| Avg | -0.18 | -0.15 | |||
| Low | -0.26 | -0.25 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.